Patents by Inventor Kevin J. Tracey

Kevin J. Tracey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170029463
    Abstract: Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.
    Type: Application
    Filed: September 8, 2016
    Publication date: February 2, 2017
    Applicant: The Feinstein Institue For Medical Research
    Inventors: Haichao Wang, Andrew E. Sama, Wei Li, Kevin J. Tracey
  • Patent number: 9458232
    Abstract: Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: October 4, 2016
    Assignee: The Feinstein Institute For Medical Research
    Inventors: Haichao Wang, Andrew E. Sama, Wei Li, Kevin J. Tracey
  • Publication number: 20160250097
    Abstract: Described herein are devices, systems and method for treating inflammatory disorders by modulating a subject's inflammatory reflex. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject in a manner which significantly reduces proinflammatory cytokines in the subject and/or provides a therapeutically effective treatment for the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.
    Type: Application
    Filed: March 13, 2008
    Publication date: September 1, 2016
    Applicant: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Howland Shaw Warren, Michael Allen Faltys
  • Publication number: 20160096016
    Abstract: Described herein are devices, systems and method of treating inflammation by vagus nerve stimulation and the delivery of an anti-inflammatory drug. In particular, described herein are methods of treating inflammation including the steps of stimulating a subject's inflammatory reflex to inhibit the immune response and administering an anti-inflammatory drug.
    Type: Application
    Filed: December 11, 2015
    Publication date: April 7, 2016
    Inventors: Kevin J. TRACEY, Mauricio ROSAS-BALLINA, Michael A. FALTYS, Ralph J. ZITNIK
  • Publication number: 20150359785
    Abstract: Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein the cholinergic agonist is selective for an ?7 nicotinic receptor. Methods for inhibiting an inflammatory cytokine cascade in a patient are also provided. The methods comprise treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an ?7 nicotinic receptor. Methods for determining whether a compound is a cholinergic agonist reactive with an ?7 nicotinic receptor are also provided. The methods comprise determining whether the compound inhibits release of a proinflammatory cytokine from a mammalian cell.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 17, 2015
    Inventors: KEVIN J. TRACEY, HONG WANG
  • Patent number: 9211409
    Abstract: Described herein are devices, systems and method of treating inflammation, including methods of treating a T-cell mediated disease. In particular, described herein are methods of treating inflammation including the steps of stimulating a subject's inflammatory reflex to inhibit the immune response and administering a T-cell modifying agent to modify the activity of splenic T-cells. Also described herein are systems for treating inflammation including an inflammatory reflex stimulation module and a T-cell response modifying module. The T-cell response modifying module typically modifies the response of splenic T-cells to enhance or otherwise regulate the effect of stimulation of the inflammatory reflex.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: December 15, 2015
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Mauricio Rosas-Ballina
  • Publication number: 20150335763
    Abstract: Disclosed are therapeutic beads comprising agents, such as nucleic acids, that bind to high mobility group box 1 (HMGB1) and methods of treating subjects with conditions that would benefit from reducing the deleterious effects of HMGB1, such as inflammatory bowel diseases, comprising administering the beads to the gastrointestinal tract of the subjects.
    Type: Application
    Filed: January 9, 2014
    Publication date: November 26, 2015
    Applicant: The Feinstein Institute For Medical Research
    Inventors: Sangeeta Chavan, Jacob Levine, Yehuda Tamari, Kevin J. Tracey, Huan Yang
  • Publication number: 20150100100
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 9, 2015
    Inventors: Kevin J. TRACEY, Jared M. HUSTON
  • Publication number: 20150023957
    Abstract: Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 22, 2015
    Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Haichao Wang, Andrew E. Sama, Wei Li, Kevin J. Tracey
  • Patent number: 8914114
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Grant
    Filed: November 17, 2004
    Date of Patent: December 16, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Jared M. Huston
  • Patent number: 8865641
    Abstract: A method of treating a fatty liver disease in a subject. The method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis, and alcoholic cirrhosis.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: October 21, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Valentin A. Pavlov, Kevin J. Tracey
  • Patent number: 8822169
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: September 2, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang
  • Patent number: 8759376
    Abstract: Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (I a) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (I a) or (VIIa). The variables of Formulae (I), (I a), (VII) and (VII a) are described herein.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: June 24, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Yousef Al-Abed, Kevin J. Tracey
  • Patent number: 8729129
    Abstract: Disclosed is a method of reducing bleed time in a subject by activation of the cholinergic anti-inflammatory pathway in said subject. The cholinergic anti-inflammatory pathway can be activated by direct or indirect stimulation of the vagus nerve. The cholinergic anti-inflammatory pathway can also be activated by administering an effective amount of cholinergic agonist or acetylcholinesterase inhibitor to the subject.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: May 20, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Carol Ann Amella, Christopher Czura
  • Patent number: 8524866
    Abstract: An antibody or an antigen binding fragment thereof which binds to mammalian ?7 subunit of a nicotinic acetylcholine receptor or its functional variant and which is an agonist of said receptor or variant. Pharmaceutical compositions comprising same. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject an antibody or an antigen-binding fragment as described herein.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: September 3, 2013
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Lihong Yang, Kevin J. Tracey
  • Patent number: 8501173
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: August 6, 2013
    Assignees: The General Hospital Corporation, The Feinstein Institute for Medical Research, University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
  • Patent number: 8391970
    Abstract: Described herein are methods, devices and systems for inhibition of granulocyte activation by appropriate stimulation of the vagus nerve. Methods of treating granulocyte-mediated disorders (including inflammatory disorders) by stimulating the vagus nerve to inhibit granulocyte activation (particularly neutrophil activation) are also described. Appropriate stimulation may be very low levels of stimulation, including stimulation that does not result in desensitization. The level of granulocyte activation may be detected and used to at least partially control stimulation.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: March 5, 2013
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Howland Shaw Warren, Christine N. Metz
  • Publication number: 20130028910
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a phamaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: February 22, 2012
    Publication date: January 31, 2013
    Applicant: The Feinstein Institute For Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20120322719
    Abstract: A method of treating a fatty liver disease in a subject. The method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis, and alcoholic cirrhosis.
    Type: Application
    Filed: June 14, 2012
    Publication date: December 20, 2012
    Applicant: The Feinstein Institute For Medical Research
    Inventors: Valentin A. Pavlov, Kevin J. Tracey
  • Patent number: 8188041
    Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: May 29, 2012
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Huan Yang